GSK-2126458
|
|
|
- CAS-Nr.
- 1086062-66-9
- Englisch Name:
- GSK-2126458
- Synonyma:
- OMipalisib;GSK2126458;CS-55;GSK458;GSK212;HYR-582;GSK-2126458;GSK-2126458-A;GSK2126458, >=98%;Omipalisib GSK458
- CBNumber:
- CB92505205
- Summenformel:
- C25H17F2N5O3S
- Molgewicht:
- 505.5
- MOL-Datei:
- 1086062-66-9.mol
|
GSK-2126458 Eigenschaften
- Schmelzpunkt:
- 187-189℃
- Siedepunkt:
- 715.6±70.0 °C(Predicted)
- Dichte
- 1.45
- storage temp.
- Refrigerator
- L?slichkeit
- Chloroform (Slightly), DMSO (Slightly), Methanol (Very Slightly, Heated)
- Aggregatzustand
- Solid
- pka
- 6.23±0.40(Predicted)
- Farbe
- White to Pale Yellow
- InChI
- InChI=1S/C25H17F2N5O3S/c1-35-25-23(32-36(33,34)24-5-3-18(26)12-21(24)27)11-17(13-29-25)15-2-4-22-20(10-15)19(7-8-28-22)16-6-9-30-31-14-16/h2-14,32H,1H3
- InChIKey
- CGBJSGAELGCMKE-UHFFFAOYSA-N
- SMILES
- C1(S(NC2=CC(C3=CC=C4C(=C3)C(C3=CC=NN=C3)=CC=N4)=CN=C2OC)(=O)=O)=CC=C(F)C=C1F
GSK-2126458 Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
GSK2126458 is a potent inhibitor of phosphoinositide 3-kinase isoforms (K
is = 19, 130, 24, and 60 pM for p110α, β, δ, and γ, respectively). It also inhibits mTOR in both mTORC1 and mTORC2 (K
is = 180 and 300 nM, respectively), as well as several common mutant forms of p110α. GSK2126458 is orally bioavailable, displays favorable pharmacokinetics, and shows efficacy in tumor growth models. GSK2126458 positively combines with inhibitors of discoidin domain receptor 1 (DDR1) inhibitor DDR1-IN-1 to suppress the growth of SNU-1040 colorectal cancer cells.
Verwenden
A highly potent inhibitor of PI3K and the mammalian target of Rapamycin.
GSK-2126458 Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
GSK-2126458 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 197)Lieferanten
1086062-66-9()Verwandte Suche:
- GSK-2126458
- GSK2126458; GSK-2126458
- 2,4-Difluoro-N-[2-methoxy-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl]benzenesulfonamide
- HYR-582
- GSK212
- 2,4-Difluoro-N-[2-Methoxy-5-[4-(pyridazin-4-yl)quinolin-6-yl]pyridin-3-yl]benzenesulfonaMide
- GSK458
- Omipalisib (GSK2126458, GSK458)
- 2,4-Difluoro-N-[2-methoxy-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl]benzenesulfonamide GSK2126458(GSK458)
- GSK 2126458
2,4-Difluoro-N-[2-methoxy-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl]benzenesulfonamide
- 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide
- GSK2126458 (GSK458)
- GSK2126458, >=98%
- GSK2126458(Omipalisib)
- GSK2126458 (GSK458);GSK458;GSK-212; GSK-2126458
- GSK2126458 (HYR-582)
- CS-55
- Omipalisib GSK2126458
- Omipalisib, 98%, a highly selective and potent inhibitor of PI3K
- Omipalisib GSK458
- Benzenesulfonamide, 2,4-difluoro-N-[2-methoxy-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl]-
- GSK-2126458 USP/EP/BP
- Omipalisib GSK2126458 GSK-2126458
- Omipalisib, 10 mM in DMSO
- GSK-2126458-A
- GSK2126458
- OMipalisib
- 1086062-66-9
- C25H17F2N5O3S
- Akt
- mTOR
- PI3K
- Inhibitors
- PI3K/Akt/mTOR
- Aromatics
- Heterocycles
- Intermediates & Fine Chemicals
- Pharmaceuticals
- Sulfur & Selenium Compounds
